Valuation: Cann Group Limited

Market Cap 8.3M 5.82M 5.12M 4.83M 4.41M 8.24M 559M 57.94M 22.45M 284M 21.86M 21.39M 926M P/E 2024
-0.23x
P/E 2025 -0.24x
Enterprise Value 84.13M 59.01M 51.9M 48.93M 44.64M 83.48M 5.66B 587M 228M 2.88B 222M 217M 9.38B EV / Sales 2024
4.54x
EV / Sales 2025 6.2x
Free-Float
78.02%
Yield 2024 *
-
Yield 2025 -
1 week-20.00%
1 month+33.33%
3 months-11.11%
6 months-20.00%
Current year-55.56%
1 week 0
Extreme 0.004
0
1 month 0
Extreme 0.003
0.01
Current year 0
Extreme 0.002
0.01
1 year 0
Extreme 0.002
0.02
3 years 0
Extreme 0.002
0.19
5 years 0
Extreme 0.002
0.44
10 years 0
Extreme 0.002
4.55
Manager TitleAgeSince
Director of Finance/CFO - 14/08/2024
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer - 01/01/2018
Director TitleAgeSince
Chairman 79 10/02/2025
Director/Board Member 59 31/03/2025
Chairman - 01/12/2025
Date Insider Type Main position Quantity % Market Cap. Importance
12/06/24 Buy

Chief Executive Officer

205,500 0.0469%
01/08/23 Buy

Director

165,515 0.0341%
01/08/23 Buy

Chairman

284,091 0.0585%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-20.00%-63.64%-96.80% 4.68M
+2.80%+10.25%+13.87%+248.14% 371M
+0.65%+3.36%-38.65%-23.76% 153M
+3.29%+10.55%+28.65%+126.80% 149M
-1.75%+12.00%-16.42%-49.09% 116M
-0.12%+3.45%-34.91%-45.08% 65.51M
Average +0.81%+1.81%-18.51%+26.70% 143.25M
Weighted average by Cap. +1.65%+6.41%-1.14%+114.35%

Financials

2024 2025
Net sales 18.36M 12.88M 11.33M 10.68M 9.74M 18.22M 1.24B 128M 49.65M 629M 48.34M 47.29M 2.05B 13.25M 9.3M 8.18M 7.71M 7.03M 13.15M 892M 92.49M 35.84M 454M 34.9M 34.14M 1.48B
Net income -51.24M -35.94M -31.61M -29.8M -27.19M -50.85M -3.45B -358M -139M -1.76B -135M -132M -5.71B -22.34M -15.67M -13.79M -12.99M -11.86M -22.17M -1.5B -156M -60.43M -766M -58.84M -57.56M -2.49B
Net Debt 70.83M 49.67M 43.69M 41.19M 37.58M 70.28M 4.77B 494M 192M 2.43B 187M 182M 7.9B 75.83M 53.18M 46.78M 44.1M 40.23M 75.24M 5.11B 529M 205M 2.6B 200M 195M 8.46B
Logo Cann Group Limited
Cann Group Limited is an Australia-based company, which is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the Company, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. It operates through cultivation of the medicinal cannabis segment. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research and good manufacturing practices (GMP) manufacturing facilities are near Mildura, Victoria.
Employees
-
Date Price Change Volume
24/09/26 A$0.004000 0.00% 212,416
23/09/26 A$0.004000 -11.11% 1,553
22/09/26 A$0.004500 +12.50% 607,405
21/09/26 A$0.004000 0.00% 1,280,548
18/09/26 A$0.004000 -20.00% 8,020,165